Epstein-Barr Virus Infection Management

Diagnostic Criteria

• The American Journal of Hematology guidelines require significantly elevated VCA-IgG (typically ≥1:640) and EA-IgG (typically ≥1:160) for CAEBV diagnosis, and clinical symptoms such as persistent fever, lymphadenopathy, hepatosplenomegaly, or debilitating fatigue must be present 1
• The standard diagnostic approach for EBV infection includes serological testing, with interpretation guided by the following table:

• IgG avidity testing can help distinguish between recent and past infection, with low avidity indicating recent infection and high avidity suggesting past infection or reactivation, and is considered for ambiguous serological patterns, with a low level of evidence 3, 1
• Quantitative EBV viral load by PCR may be considered to confirm active viral replication in cases of persistent or severe symptoms, with a moderate level of evidence 1

Management and Treatment

• The Infectious Diseases Society of America recommends a primarily supportive management approach for EBV-related tonsillitis, including rest, adequate hydration, and symptomatic relief, as well as avoiding contact sports for at least 8 weeks or while splenomegaly is present, and avoiding unnecessary antibiotics unless bacterial co-infection is confirmed 4
• Antiviral therapy may be considered for severe or persistent cases of chronic active EBV infection, with a moderate level of evidence 5
• Intravenous immunoglobulin (IVIG) therapy may be considered for patients with low IgG levels, severe recurrent infections, life-threatening infections, or documented bacterial infections with insufficient response to antibiotics, with a low level of evidence 5
• Rituximab may be considered in post-allogenic HSCT patients with EBV reactivation, with a moderate level of evidence 5

Monitoring and Prevention

• Patients with chronic active EBV infection should be monitored for complications such as EBV-related hemophagocytic lymphohistiocytosis, T-cell or NK-cell lymphoproliferative disorders/lymphomas, and hematological abnormalities, with a moderate level of evidence 5, 1
• Immunocompromised patients are at increased risk of lymphoproliferative disorders, and patients on immunosuppressive therapy who develop primary EBV infection are at increased risk for severe complications and lymphoproliferative disorders, with a high level of evidence 4, 6
• Prevention measures include frequent handwashing with soap and water, avoiding sharing utensils, glasses, toothbrushes, or food, avoiding kissing or intimate contact during the acute phase, and covering coughs and sneezes, with a moderate level of evidence 7
• The American Gastroenterological Association and European Crohn’s and Colitis Organisation recommend considering EBV IgG screening before starting immunomodulator therapy to identify EBV seronegative patients, in whom anti-TNF monotherapy might be preferred over thiopurines 6
• The Haematologica society recommends monitoring for EBV reactivation, and considering quantitative EBV viral load by PCR in peripheral blood, in patients with a history of hematopoietic stem cell transplant (HSCT), and being vigilant for signs of post-transplant lymphoproliferative disorders (PTLD) 8

Immunoglobulin Replacement Therapy

• The American Society of Hematology and European Hematology Association recommend monitoring immunoglobulin levels, particularly IgG levels, in patients with Epstein-Barr virus infection, and considering immunoglobulin replacement therapy if IgG levels are <400 mg/dl or if the patient has experienced severe recurrent infections, life-threatening infections, or documented bacterial infections with insufficient response to antibiotics 5